Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.

Published on Jan 21, 2021in Annals of the Rheumatic Diseases19.103
· DOI :10.1136/ANNRHEUMDIS-2020-219517
Angel Y S Wong21
Estimated H-index: 21
(Lond: University of London),
Brian MacKenna13
Estimated H-index: 13
(University of Oxford)
+ 29 AuthorsHenry Drysdale9
Estimated H-index: 9
(University of Oxford)
Sources
Abstract
Objectives To assess the association between routinely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical platform. Methods We conducted two cohort studies from 1 March to 14 June 2020. Working on behalf of National Health Service England, we used routine clinical data in England linked to death data. In study 1, we identified people with an NSAID prescription in the last 3 years from the general population. In study 2, we identified people with rheumatoid arthritis/osteoarthritis. We defined exposure as current NSAID prescription within the 4 months before 1 March 2020. We used Cox regression to estimate HRs for COVID-19 related death in people currently prescribed NSAIDs, compared with those not currently prescribed NSAIDs, accounting for age, sex, comorbidities, other medications and geographical region. Results In study 1, we included 536 423 current NSAID users and 1 927 284 non-users in the general population. We observed no evidence of difference in risk of COVID-19 related death associated with current use (HR 0.96, 95% CI 0.80 to 1.14) in the multivariable-adjusted model. In study 2, we included 1 708 781 people with rheumatoid arthritis/osteoarthritis, of whom 175 495 (10%) were current NSAID users. In the multivariable-adjusted model, we observed a lower risk of COVID-19 related death (HR 0.78, 95% CI 0.64 to 0.94) associated with current use of NSAID versus non-use. Conclusions We found no evidence of a harmful effect of routinely prescribed NSAIDs on COVID-19 related deaths. Risks of COVID-19 do not need to influence decisions about the routine therapeutic use of NSAIDs.
Download
References32
Newest
#1Zaid Imam (Beaumont Health)H-Index: 8
#2Fadi Odish (Beaumont Health)H-Index: 3
Last. Alexandra Halalau (Oakland University)H-Index: 8
view all 10 authors...
INTRODUCTION: Higher comorbidity and older age have been reported as correlates of poor outcomes in COVID-19 patients worldwide, however US data is scarce. We evaluated mortality predictors of COVID-19 in a large cohort of hospitalized patients in the US. DESIGN: Retrospective, multicenter cohort of inpatients diagnosed with COVID-19 by RT-PCR from March 1-April 1,2020 was performed, and outcome data evaluated from March 1-April 17, 2020. Measures included demographics, comorbidities, clinical p...
Source
#1Lars Christian LundH-Index: 10
Last. Anton Pottegård (University of Southern Denmark)H-Index: 37
view all 11 authors...
BACKGROUND Concerns over the safety of non-steroidal anti-inflammatory drug (NSAID) use during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been raised. We studied whether use of NSAIDs was associated with adverse outcomes and mortality during SARS-CoV-2 infection. METHODS AND FINDINGS We conducted a population-based cohort study using Danish administrative and health registries. We included individuals who tested positive for SARS-CoV-2 during the period 27 Februa...
Source
#1Ehud Rinott (BGU: Ben-Gurion University of the Negev)H-Index: 10
#2Eran Kozer (TAU: Tel Aviv University)H-Index: 23
Last. Ilan Youngster (TAU: Tel Aviv University)H-Index: 24
view all 5 authors...
Abstract Objective It was recently suggested that Ibuprofen might increase the risk for severe and fatal COVID-19 disease and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in patients with COVID-19 was associated with more severe disease, compared to patients using paracetamol or no antipyretics. Methods In a retrospective cohort study of patients with COVID-19 from Shamir Medical Center, Israel, we monitored any use of ibuprofen from a week p...
Source
#1Mahmoud Yousefifard (IUMS: Iran University of Medical Sciences)H-Index: 28
#2Alireza Zali (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 18
Last. Saeed Safari (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 24
view all 6 authors...
BACKGROUND: Since there is still no definitive conclusion regarding which non-steroidal anti-inflammatory drugs (NSAIDs) are most effective and safe in viral respiratory infections, we decided to evaluate the efficacy and safety of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for COVID-19. METHODS: A search was performed in Medline (via PubMed), Embase, and CENTRAL databases until 23 March 2020. Clinical trials on application of N...
Source
Coronavirus disease 2019 (COVID-19) infection causes acute lung injury, resulting from aggressive inflammation initiated by viral replication. There has been much speculation about the potential role of non-steroidal inflammatory drugs (NSAIDs), which increase the expression of angiotensin-converting enzyme 2 (ACE2), a binding target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter the host cell, which could lead to poorer outcomes in COVID-19 disease. The aim of this st...
Source
#1Ben Goldacre (University of Oxford)H-Index: 39
#2Brian MacKenna (University of Oxford)H-Index: 13
Ben Goldacre and Brian MacKenna argue that hospital medicines data has huge potential to improve patient care and that its use for public good is being blocked by cultural, contractual, and political barriers, rather than technical complexity
Source
#1Elizabeth A. Williamson (Lond: University of London)H-Index: 72
#2Alex J Walker (University of Oxford)H-Index: 23
Last. Ben Goldacre (University of Oxford)H-Index: 39
view all 30 authors...
Coronavirus disease 2019 (COVID-19) has rapidly affected mortality worldwide1. There is unprecedented urgency to understand who is most at risk of severe outcomes, and this requires new approaches for the timely analysis of large datasets. Working on behalf of NHS England, we created OpenSAFELY—a secure health analytics platform that covers 40% of all patients in England and holds patient data within the existing data centre of a major vendor of primary care electronic health records. Here we us...
Source
#1Min Hyuk Choi (Yonsei University)H-Index: 8
#2Hyunmin AhnH-Index: 2
Last. Seok Hoon Jeong (Yonsei University)H-Index: 18
view all 8 authors...
A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II recep...
Source
#1Milena A. Gianfrancesco (UCSF: University of California, San Francisco)H-Index: 23
#2Kimme L. HyrichH-Index: 65
Last. Philip Robinson (UQ: University of Queensland)H-Index: 84
view all 28 authors...
Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease. Methods Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking stat...
Source
#1Giuseppe Mancia (University of Milano-Bicocca)H-Index: 166
#2Federico Rea (University of Milano-Bicocca)H-Index: 53
Last. Giovanni Corrao (University of Milano-Bicocca)H-Index: 74
view all 5 authors...
Abstract Background A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covi...
Source
Cited By12
Newest
#1Lisa PilgramH-Index: 6
#2M. SchonsH-Index: 4
view all 13 authors...
OBJECTIVE The Coronavirus Disease-2019 (COVID-19) pandemic has brought opportunities and challenges, especially for health services research based on routine data. In this article we will demonstrate this by presenting lessons learned from establishing the currently largest registry in Germany providing a detailed clinical dataset on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infected patients: the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS). METHODS LEOSS...
Source
#1Jonathan G. Quicke (Keele University)H-Index: 7
#2P.G. Conaghan (University of Leeds)H-Index: 23
Last. George Peat (Keele University)H-Index: 55
view all 4 authors...
This "Year in review" presents a selection of research themes and individual studies from the clinical osteoarthritis (OA) field (epidemiology and therapy) and includes noteworthy descriptive, analytical-observational, and intervention studies. The electronic database search for the review was conducted in Medline, Embase and medRxiv (15th April 2020 to 1st April 2021). Following study screening, the following OA-related themes emerged: COVID-19; disease burden; occupational risk; prediction mod...
Source
#1Leandra de Almeida Ribeiro Oliveira (UFG: Universidade Federal de Goiás)H-Index: 3
#2Arthur Christian Garcia da Silva (UFG: Universidade Federal de Goiás)
Last. Dâmaris Silveira (UnB: University of Brasília)H-Index: 19
view all 8 authors...
Source
#1Kevin L. Winthrop (OHSU: Oregon Health & Science University)H-Index: 72
#2Richard J. Whitley (UAB: University of Alabama at Birmingham)H-Index: 123
Last. Daniel Aletaha (Medical University of Vienna)H-Index: 85
view all 3 authors...
It is a rare opportunity to enter the backside (hopefully) of a pandemic. Not since the Spanish influenza has the world experienced such a level of contagion. While we averted a worldwide crisis 20 years ago with the first SARS virus infection, SARS-CoV-2 with its unique ability to transmit easily among asymptomatic persons has altered our 21st-century appreciation and respect for viral diseases. From a scientific standpoint, we believe the scientific collaboration and innovation of the last 12 ...
Source
#1Róbert Almási (PTE: University of Pécs)H-Index: 6
Osszefoglalo. Az uj koronaviruskent megismert SARS-CoV-2-fertőzes legsulyosabb szovődmenyekent a gyulladasos folyamatok jelatvivő molekulainak elszabadulasa - az un. citokinvihar - kritikus legzesi elegtelenseggel tarsulo akut respiracios diszfunkcios szindromat vagy tobbszervi gyulladasos szindromat okoz. Mostanaig igazolodott, hogy a fertőzesek legnagyobb reszben tunetmentesen vagy enyhe tunetekkel zajlanak. A betegseg minden szakaszaban előfordulhat enyhe vagy kozepsulyos, ritkabban intenziv ...
Source
#1Xin Xu (Peking Union Medical College)H-Index: 29
#2Jun Xia (Soochow University (Suzhou))H-Index: 1
Last. Yili Yang (Peking Union Medical College)H-Index: 1
view all 0 authors...
COVID-19 is often characterized by dysregulated inflammatory and immune responses. It has been shown that the Traditional Chinese Medicine formulation Qing-Fei-Pai-Du decoction (QFPDD) is effective in the treatment of the disease, especially for patients in the early stage. Our network pharmacology analyses indicated that many inflammation and immune-related molecules were the targets of the active components of QFPDD, which propelled us to examine the effects of the decoction on inflammation. W...
Source
#2Roxana Valeria Alasino (CONICET: National Scientific and Technical Research Council)H-Index: 5
Last. Dante Miguel Beltramo (CONICET: National Scientific and Technical Research Council)H-Index: 7
view all 7 authors...
We analyze changes in circulating platelets in COVID-19 positive patients who received conventional treatment Dexamethasone and Enoxaparin (Dexa-Enoxa) compared to patients treated with conventional therapy plus nebulization with alkaline hypertonic ibuprofenate (AHI). Results show that after 24 h of nebulization with AHI, circulating platelets shows an increase about 40% at 24 h and reach 65% at 96 h. In patients with platelets content below 200,000 by microliter the increase was 49% and 79% at...
Source
#1Luísa Prada (University of Lisbon)H-Index: 2
#2Catarina Duarte Santos (University of Lisbon)H-Index: 2
Last. Daniel CaldeiraH-Index: 22
view all 6 authors...
Nonsteroidal anti-inflammatory drugs (NSAIDs) were thought to increase the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus entrance into cells. Hence, it was suggested in the media that NSAIDs could lead to a higher risk of infection and/or disease severity. To determine the existence or absence of this association, we aimed to systematically evaluate the risk of SARS-CoV-2 infection and mortality and the risk of severe coronavirus disease 2019 (COVID-19) associated with previ...
Source
#1Nicholas Moore (University of Bordeaux)H-Index: 75
#2Pauline Bosco-Levy (University of Bordeaux)H-Index: 7
Last. Cécile Droz-Perroteau (University of Bordeaux)H-Index: 11
view all 5 authors...
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been discouraged for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, fearing that they could increase the risk of infection or the severity of SARS-CoV-2. Original studies providing information on exposure to NSAIDs and coronavirus disease 2019 (COVID-19) outcomes were retrieved and were included in a descriptive analysis and a meta-analysis with Cochrane Revue Manager (REVMAN 5.4), using inverse varianc...
Source
#1Emanuela Ricciotti (UPenn: University of Pennsylvania)H-Index: 28
#2Krzysztof Laudanski (UPenn: University of Pennsylvania)H-Index: 13
Last. Garret A. FitzGerald (UPenn: University of Pennsylvania)H-Index: 144
view all 3 authors...
Abstract null null Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterized by a wide spectrum of symptom severity, which is manifested at different phases of infection and demands different levels of care. Viral load, host innate-immune response to SARS-CoV-2, and comorbidities have a direct impact on the clinical outcomes of COVID-19 patients and determine the diverse disease trajectories. The initial SARS-CoV-2 penetrance an...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.